CASBF (CASBF) Stock Price & Analysis
CASBF (CASBF) rose 0.00% to USD 3.15 as of July 25, 2026 at 15:44 UTC, according to Nexqual real-time market data.
CASBF last closed at USD 3.15; the session ranged USD 2.6–2.6 on volume of 200 shares. Market capitalization is $776.95M, with a 52-week range of USD 2.6–6.99 (PNK). Source: Nexqual, July 25, 2026 at 15:44 UTC.
Key Statistics (as of July 25, 2026 at 15:44 UTC)
| Price | USD 3.15 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 3.15 |
| Open | USD 2.6 |
| Day Range | USD 2.6 – 2.6 |
| 52-Week Range | USD 2.6 – 6.99 |
| Volume | 200 shares |
| Market Cap | $776.95M |
| Exchange | PNK |
Technical Analysis (CASBF)
Nexqual's technical model rates CASBF "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 15:44 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 75.47 (overbought) |
| vs SMA50 | Above (USD 3.11) |
| MACD | 0.03 (positive) |
Analyst Ratings (CASBF)
Wall Street analysts rate CASBF "None", per Nexqual as of July 25, 2026 at 15:44 UTC.
| Consensus Rating | None |
|---|
Earnings (CASBF)
| Next Earnings Date | 2026-08-20 |
|---|
Source: Nexqual, July 25, 2026 at 15:44 UTC.
Financials & Fundamentals (CASBF)
| Total Revenue | $1.12B |
|---|---|
| Revenue Growth (YoY) | +38.70% |
| Gross Margin | +75.36% |
| Operating Margin | -15.19% |
| Profit Margin | -0.09% |
| ROE | -0.02% |
| Debt / Equity | 23.59 |
| Current Ratio | 4.11 |
| Total Cash | $2.41B |
| Total Debt | $1.16B |
| Free Cash Flow | $-351.57M |
Source: Nexqual, July 25, 2026 at 15:44 UTC.
Financial Health Score (CASBF)
Nexqual rates CASBF's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 15:44 UTC.
| Growth | Strong — Revenue +28% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 75%, operating -15% |
| Balance Sheet | Strong — $2.41B cash vs $1.16B debt, net cash position |
| Cash Flow | Weak — FCF negative: -$352M, burning cash |
| Efficiency | Critical — ROE -0%, ROA -0.8% |
Ownership (CASBF)
| Insider Ownership | +26.85% |
|---|---|
| Institutional Ownership | +16.17% |
| Shares Outstanding | 132.67M |
| Float | 159.89M |
Source: Nexqual, July 25, 2026 at 15:44 UTC.
Leadership (CASBF)
CASBF is led by Xuefeng Yu (age 61), Co-Founder, Executive Chairman, CEO & GM, per Nexqual as of July 25, 2026 at 15:44 UTC.
| Co-Founder, Executive Chairman, CEO & GM | Xuefeng Yu (age 61) |
|---|---|
| COO, Deputy GM & Executive Director | Shou-Bai Chao (age 62) |
| Chief Commercial Officer, Deputy GM & Executive Director | Jing Wang (age 44) |
| Co-Founder, Deputy GM & Chief Scientific Officer | Tao Zhu (age 52) |
| Senior Director of New Technology Department | Chunlin Xin |
Major Backers & Investors (CASBF)
Notable institutional backers of CASBF include New World Fund Inc, DFA INVESTMENT TRUST CO-The Emerging Markets Small Cap Series, according to Nexqual as of July 25, 2026 at 15:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| New World Fund Inc | 0.62% |
| DFA INVESTMENT TRUST CO-The Emerging Markets Small Cap Series | 0.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.09% |
| BlackRock | 0.86% |
Source: Nexqual, July 25, 2026 at 15:44 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SHTDY | Sinopharm Group Co. Ltd. | USD 10.73 | ▼ 0.89% |
| SFOSF | SHANGHAI FOSUN PHARMACEUTICAL G | USD 2.2 | ▲ 0% |
| 6185.HK | CANSINOBIO | HKD 23.38 | ▼ 3.94% |
| SHTDF | SINOPHARM GROUP CO. LTD. | USD 2.13 | ▲ 0% |
| LZAGY | Lonza Group AG | USD 67.09 | ▲ 2.07% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:44 UTC. This page is informational and not investment advice.